Research progress of cyclosporine A in treatment of recurrent abortion

Abstract

Recurrent spontaneous abortion (RSA) is one of the common complications of pregnancy in obstetrics and gynecology, and it seriously threatens the physical and mental health of women in the reproductive period. The etiology of RSA is complex, and based on the basic national conditions and clinical practice in China, it is found that the incidence rate of RSA among women of childbearing age increases year by year. At present, the etiology of some patients with RSA is unknown, and some studies have reported that its pathogenic factors are closely related to immune abnormalities. At present, immunization-related therapeutic scheme of RSA has attracted more and more attention from scholars. Many studies have found that the immunosuppressive agent A (cyclosporine A, CsA) has an affirmative effect on the prevention and treatment of RSA by benign regulation of maternal-fetal immune tolerance and positive regulation of trophoblast biological function. However, the application of CsA in the reproduction field is still in the exploratory stage, and there are no standardized treatment standards, large samples and high quality clinical trials. In view of this, we reviewed the mechanism of action of CsA in the treatment of RSA and the research progress of combination therapy in recent years, in order to provide new theoretical support for the subsequent clinical treatment of RSA.